For Corporate Acquirers
Our flagship M&A Report — $25,000 per target — is an independent, fully cited check on banker- and target-supplied materials, covering clinical adoption, manufacturing integration, regulatory alignment, and IP strength. Every material claim traced to a public source — never fabricated. Annual licensing available for acquirers evaluating many targets a year.
Multi-Target Screening
Rank multiple targets — bolt-ons, build-vs-buy candidates, or strategic options — before committing to a single LOI
| Company | Score | Status |
|---|
De-Risk Your Pipeline
Surface and quantify risk before engagement letters.
What We Find
Six headline categories within our 20-category diligence framework.
Clinical adoption as deal risk
Integration-failure risk on unvalidated targets
Post-close remediation exposure
Differentiator analysis with effect-size disclosure
Does the platform roadmap align with target capabilities? We validate technical synergies before integration begins.
Quality, scale, and supplier consolidation risks. We identify design-for-manufacturing gaps before acquisition.
FDA pathway viability and compliance readiness. Hidden regulatory risk = 12-18 month delays and $1-3M remediation.
Patent defensibility and freedom-to-operate. We assess IP quality before integrating into your platform.
Reimbursement alignment and customer overlap. Cross-category pattern intelligence benchmarked against 800+ outcome-labeled biomedical companies in our cohort substrate.
Will clinicians adopt the integrated solution? Workflow disruption kills post-close value faster than technical issues.
Pricing
A rapid screen for inbound targets, our flagship $25,000 M&A Report for finalists, and a custom engagement for platform acquisitions — with annual licensing for repeat acquirers.
Also available: Annual licensing for acquirers evaluating many targets a year — a standing M&A Report relationship across your pipeline. Contact us →
Acquisitions without clinical-technical validation carry materially higher integration-failure risk and can absorb significant post-close remediation cost.
Deal Lifecycle
Risk validation from target screening through post-close integration
Quick Screen on inbound targets to identify clinical and manufacturing red flags early
M&A Report with integration planning and board-level recommendations
Strategic DD report with synergy quantification and risk remediation roadmap
Integration checkpoints and close-related Q&A support
Milestone tracking and integration risk surveillance
How we'd diligence a target
We'd rather show you the framework run on cases your corp-dev team already knows than ask you to trust an unnamed testimonial. Each card is a public retrospective with the integration risk our M&A Report would have surfaced pre-LOI.
200K+ implants recalled, Chapter 11 in 2024. The materials-chemistry and complaint-trend signals were knowable; we walk what corp-dev should have asked the QMS team.
Read the retrospective →FDA warning letter forced a category change post-IPO, halting US sales for 18 months. The regulatory exposure was visible in public filings before the deal cycle.
Read the retrospective →First FDA-cleared prescription digital therapeutic, $1.6B SPAC, bankrupt in 24 months. We trace the payer-coverage and prescribing-economics signals available pre-deal.
Read the retrospective →Named corporate engagements remain confidential until the acquirer authorizes attribution. Public retrospectives are how we let buyers verify our framework before signing.
A standing M&A Report relationship for acquirers evaluating many targets a year — priority M&A Reports across your pipeline, quarterly risk briefings, and continuous coverage. Every deliverable independent of deal parties, fully cited, and drawn from our proprietary multi-source substrate.
Talk to Arvind, MD →Talk to Arvind about the flagship M&A Report, or start with a Quick Screen to filter inbound targets. Annual licensing available for repeat acquirers.
The 20 clinical, manufacturing, and regulatory risks that derail acquisitions. Created by Arvind Ravinutala, MD and Aswini Ravinutala, BME.
Download the ChecklistNo email required. No paywall.